Product Update:

empagliflozin plus linagliptin 10mg/5mg, 25mg/5mg film-coated tablets (Glyxambi®)  
Boehringer Ingelheim Ltd.

07 April 2017 (Issued July 2019)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**empagliflozin/linagliptin (Glyxambi®)** is accepted for restricted use within NHS Scotland.

**Indication under review:** in adults aged 18 years and older with type 2 diabetes mellitus:
- To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi® do not provide adequate glycaemic control
- When already being treated with the free combination of empagliflozin and linagliptin

**SMC restriction:** Restricted to use in line with the previous SMC advice on empagliflozin and linagliptin.

In patients for whom this combination is appropriate, empagliflozin/linagliptin (Glyxambi®) offers a single tablet at a lower cost per dose compared with the individual components.

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 11 June 2019.

Chairman, Scottish Medicines Consortium